Pre-made Ticilimumab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-569
Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||5ggu:HL:AB/5ggv:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine|
|Conditions Active||Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer|
|Conditions Discontinued||Diffuse large B-cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes|
|Development Tech||Abgenix XenoMouse|